Lind Kevin Robert 4
4 · Avalo Therapeutics, Inc. · Filed Jan 5, 2026
Insider Transaction Report
Form 4
Lind Kevin Robert
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-12-31$14.74/sh+848$12,500→ 848 totalExercise: $18.16Exp: 2035-12-31→ Common Stock (848 underlying)
Footnotes (1)
- [F1]The options were granted on December 31, 2025, and are 100% vested.